Surrozen, Inc./DE (SRZNW) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
171 OYSTER POINT BLVD SOUTH SAN FRANCISCO, CA 94080 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments, including: | 34,565 | 36,043 | 75,800 | 123,500 | 987 | |||
| Cash and cash equivalent | 34,565 | 36,043 | 24,690 | 33,091 | 987 | |||
| Short-term investments | 102,296 | 137,520 | ||||||
| Other undisclosed cash, cash equivalents, and short-term investments | (51,186) | (47,111) | ||||||
| Restricted cash and investments | 33,496 | |||||||
| Receivables | 2,039 | 2,152 | 1,978 | |||||
| Prepaid expense | 790 | |||||||
| Other undisclosed current assets | 2,328 | 2,937 | 3,527 | (51,807) | ||||
| Total current assets: | 38,932 | 41,132 | 81,305 | 105,189 | 1,778 | |||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 7,801 | 1,889 | 3,268 | 4,582 | ||||
| Property, plant and equipment | 562 | 1,969 | 3,630 | 4,794 | ||||
| Long-term investments and receivables | 21,655 | |||||||
| Long-term investments | 21,655 | |||||||
| Asset, held-in-trust | 91,998 | |||||||
| Restricted cash and investments | 688 | 688 | 405 | 405 | ||||
| Other noncurrent assets | 331 | 402 | 827 | 549 | ||||
| Other undisclosed noncurrent assets | 153 | |||||||
| Total noncurrent assets: | 9,535 | 4,948 | 8,130 | 31,985 | 91,998 | |||
| TOTAL ASSETS: | 48,467 | 46,080 | 89,435 | 137,174 | 93,775 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 5,486 | 4,651 | 7,506 | 11,380 | ||||
| Accounts payable | 306 | 525 | 658 | 2,718 | ||||
| Accrued liabilities | 5,180 | 4,126 | 6,848 | 8,662 | ||||
| Other undisclosed current liabilities | 1,829 | 2,497 | 2,226 | 2,193 | ||||
| Total current liabilities: | 7,315 | 7,148 | 9,732 | 13,573 | ||||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation: | 5,600 | |||||||
| Liabilities, other than long-term debt | 6,640 | 882 | 3,376 | |||||
| Operating lease, liability | 6,640 | 882 | 3,376 | 5,600 | ||||
| Other undisclosed noncurrent liabilities | 55,892 | 115 | 326 | 2,701 | ||||
| Total noncurrent liabilities: | 62,532 | 997 | 3,702 | 13,901 | ||||
| Other undisclosed liabilities | 6,914 | |||||||
| Total liabilities: | 69,847 | 8,145 | 13,434 | 27,474 | 6,914 | |||
| Temporary equity, including noncontrolling interest | 81,861 | |||||||
| Equity | ||||||||
| Equity, attributable to parent, including: | (21,380) | 37,935 | 76,001 | 109,700 | 5,000 | |||
| Common stock | 3 | 4 | ||||||
| Additional paid in capital | 263,879 | 259,630 | 254,892 | 252,464 | 7,122 | |||
| Accumulated other comprehensive loss | (241) | (119) | ||||||
| Accumulated deficit | (285,259) | (221,695) | (178,653) | (142,649) | (2,122) | |||
| Other undisclosed equity, attributable to parent | 0 | |||||||
| Total equity: | (21,380) | 37,935 | 76,001 | 109,700 | 5,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 48,467 | 46,080 | 89,435 | 137,174 | 93,775 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 10,655 | 12,500 | |||||
| Gross profit: | 10,655 | 12,500 | |||||
| Operating expenses | (36,194) | (45,780) | (56,839) | (54,391) | |||
| Operating loss: | (25,539) | (45,780) | (44,339) | (54,391) | |||
| Nonoperating income (expense) | (17,741) | 2,912 | 8,227 | (362) | |||
| Investment income, nonoperating | 1,693 | 2,340 | 673 | (33) | |||
| Other nonoperating income (expense) | (19,321) | 398 | 7,554 | (329) | |||
| Loss from continuing operations: | (43,280) | (42,868) | (36,112) | (54,753) | |||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (54,753) | ✕ | |
| Other undisclosed net income (loss) | (20,284) | (174) | 108 | 105 | |||
| Net loss available to common stockholders, diluted: | (63,564) | (43,042) | (36,004) | (54,648) | |||
Comprehensive Income ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (63,564) | (43,042) | (36,004) | (54,648) | |||
| Other comprehensive income (loss) | 241 | (122) | (119) | ||||
| Comprehensive loss, net of tax, attributable to parent: | (63,564) | (42,801) | (36,126) | (54,767) | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.